Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM)
Sheheryar Kabraji(Roswell Park Comprehensive Cancer Center), Nancy U. Lin(Dana-Farber Cancer Institute), Carey K. Anders(Duke University), Melissa E. Hughes(Dana-Farber Cancer Institute), Akshara Singareeka Raghavendra(The University of Texas MD Anderson Cancer Center), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Liangge Hsu(Brigham and Women's Hospital), Maria Gule-Monroe(The University of Texas MD Anderson Cancer Center), Jean J. Zhao(Harvard University), Alyssa Pereslete(Florida International University), Jing Ni(Dana-Farber Cancer Institute), Heather Moore(Clinical Research Institute), Eric P. Winer(University of Vermont), Yanzhi Wang(Sichuan University), Amanda E.D. Van Swearingen(Duke Cancer Institute), Chris Lascola(Clinical Research Institute), Sarah Sammons(Dana-Farber Cancer Institute)
Cited by 6
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k